Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors

  1. Le Gouill, S.
  2. Długosz-Danecka, M.
  3. Rule, S.
  4. Zinzani, P.L.
  5. Goy, A.
  6. Smith, S.D.
  7. Doorduijn, J.K.
  8. Panizo, C.
  9. Shah, B.D.
  10. Davies, A.J.
  11. Eek, R.
  12. Jacobsen, E.
  13. Kater, A.P.
  14. Robak, T.
  15. Jain, P.
  16. Calvo, R.
  17. Tao, L.
  18. Wang, M.
Aldizkaria:
Haematologica

ISSN: 1592-8721,  0390-6078

Argitalpen urtea: 2024

Alea: 109

Zenbakia: 1

Orrialdeak: 343-350

Mota: Gutuna

DOI: 10.3324/HAEMATOL.2022.282469 GOOGLE SCHOLAR lock_openSarbide irekia editor

Garapen Iraunkorreko Helburuak

Datuen iturria: Scopus